Biogen and Eisai Secure China Approval for LEQEMBI Subcutaneous Formulation
Event summary
- China’s NMPA approved LEQEMBI® (lecanemab) subcutaneous formulation for early Alzheimer’s disease initiation treatment.
- The approval follows a Priority Review designation and is based on Phase 3 Clarity AD study data and subcutaneous sub-studies.
- LEQEMBI SC-AI offers a once-weekly, self-administered autoinjector option, reducing clinic visits and healthcare resource use.
- Eisai and Biogen plan to launch the product during Eisai’s FY 2026, ending March 31, 2027.
- China has an estimated 17 million patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease.
The big picture
The approval of LEQEMBI SC-AI in China marks a strategic milestone for Biogen and Eisai, expanding their reach in the world’s most populous country. This move aligns with broader industry trends toward more convenient, patient-centric treatment options for neurodegenerative diseases. The subcutaneous formulation could set a new standard for Alzheimer’s disease management, potentially influencing global regulatory and commercial strategies.
What we're watching
- Market Penetration
- The pace at which LEQEMBI SC-AI adoption will grow in China’s vast early Alzheimer’s disease patient population.
- Regulatory Dynamics
- Whether the subcutaneous formulation approval will accelerate regulatory reviews in other countries.
- Competitive Positioning
- How Biogen and Eisai will leverage this approval to strengthen their leadership in anti-amyloid therapies.
Related topics